Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,204 results that match your search.22,204 results
  • George W Bush The US government has moved to make generic drugs more widely available. In an announcement on October 22, President George W Bush said he would adopt key recommendations made by the FTC in its report into competition in the industry.
  • The decision in Kenman Kandy to allow the registration of a three-dimensional, bug-shaped sweet will have significant implications for existing and future shape trade mark applications in Australia. Colin Oberin and Ben Arnall examine the consequences for brand owners
  • Following last year's Baby-Dry decision, trade mark attorneys in Europe have been exploring how to protect novel marks. The new Community Design gives them another tool. Ingrid Hering reports
  • For all trade marks owners in the US, this will remove a competitive disadvantage
  • Practitioners in the US and Canada face the prospect of exciting changes in the future as courts tackle fundamental issues about the limits of trade mark and copyright protection. James Nurton reports
  • ? China: The World Summit on Intellectual Property is to be held in Beijing in April 2003. It will be sponsored jointly by WIPO and the Chinese Government.
  • Attorneys in the US have welcomed important changes to the USPTO reexamination practice, passed by the Senate in October. Under the changes, the reexamination process should prove much more attractive, particularly to third parties.
  • Alice Turinas and Bart Showalter compare data protection regulations in the US and Europe and reveal some of the pitfalls that await companies doing business internationally
  • Pursuant to the Mexican Law of Industrial Property, the owner or an authorized licensee of a registered mark must use that mark in commerce. If the mark is not used within a three year period, although it will remain in full force until its renewal time, it will be also contestable, and in consequence any interested third party could file a cancellation action against it on non-use basis.
  • An action to revoke its patent on the drug Videx EC threatens to limit further Bristol-Myers Squibb's (BMS) rights to sell Aids medicines in Thailand. Three Aids patients and the Foundation for Consumers, a local group, claim that the US pharmaceutical company did not invent the drug and so should not be allowed to own the rights to it in Thailand. According to the plaintiffs, the drug is a product of collaboration between BMS and the US National Institutes of Health (NIH).